Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment.
The acquisition of Faeth Therapeutics brings its lead asset, PIKTOR, in development across solid tumor settings, into Sensei’s pipeline, which is an investigational all-oral combination targeting the PI3K/AKT/mTOR pathway.
Private Placement
Concurrently, the company has secured a definitive agreement for a private placement financing expected to yield approximately $200 million, aimed at advancing PIKTOR through key clinical milestones, including a Phase 2 trial in advanced endometrial cancer.
Sensei expects to use the proceeds primarily to advance PIKTOR, as well as the initiation of a Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year-end 2026, with remaining proceeds for general corporate purposes and completion of Sensei’s ongoing Phase 1/2 trial of solnerstotug.
Technical Analysis
Sensei Biotherapeutics is currently trading 0.6% below its 20-day simple moving average (SMA) and 2.5% below its 100-day SMA, reflecting some short-term weakness. Over the past 12 months, shares have decreased by 2.91%, and they are positioned closer to their 52-week lows than highs, suggesting ongoing challenges in gaining upward momentum.
The RSI stands at 45.95, indicating neutral territory, while the MACD is below its signal line, suggesting bearish pressure on the stock. The combination of neutral RSI and bearish MACD indicates mixed momentum, reflecting uncertainty in the stock’s near-term direction.
- Key Resistance: $9.50
- Key Support: $8.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $181.11. Recent analyst moves include:
- HC Wainwright & Co.: Downgraded to Neutral (Oct. 30, 2025)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Sensei Biotherapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Neutral (Score: 50.4) — The stock is performing in line with the broader market.
The Verdict: Sensei Biotherapeutics’ Benzinga Edge signal reveals a mixed performance outlook. While the momentum score indicates a neutral stance, the recent acquisition may provide a necessary boost to its growth trajectory.
SNSE Price Action: Sensei Biotherapeutics shares were up 229.90% at $30.12 at the time of publication on Wednesday. The stock is trading at a new 52-week high.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wednesday Nvidia Earnings Focus: Without Jensen Huang, Who Else Can Tell a Good AI Story?
Nvidia’s Q3 report is expected to show revenue of $109 billion and net profit YoY growth of about 90%, but Jensen Huang’s sudden departure has shifted attention away from the financial results. HSBC downgraded its rating from “Buy” to “Hold” and slashed its price target to $170, while Morgan Stanley is concerned the company may postpone issuing guidance for next year. The market is now focused on the selection of a permanent CEO, whether the target of 70% revenue growth by FY2028 can be achieved, as well as risks related to Rubin mass production, AI client financing, and export controls. This earnings report will be a crucial test of whether Nvidia can break free from reliance on Jensen Huang.
U.S. Stock Market Preview | The three major stock index futures show mixed movements; Nvidia earnings, Anthropic IPO, and Federal Reserve minutes to be released this week; Intel sued by shareholders
Before the U.S. stock market opens on Monday, November 16th, the three major U.S. stock index futures showed mixed performance.
Gold steadies after hitting lowest since October 2025, hawkish Fed caps gains
SemiAnalysis Significantly Lowers AI Computing Power Forecast: 2028 Capital Expenditure Projection Cut by Nearly 30%, Five-Year Wafer Shipment Area Reduced by 17%, Nvidia Hit the Hardest
SemiAnalysis has lowered its forecast for global AI accelerator capital expenditure in 2028 by 28% and cut the 2030 forecast by 40%. The cumulative shipment area of accelerator chips from 2026 to 2030 has been revised down by 17%, demand for HBM in 2028 has been slashed by 30%, and power consumption demand in 2030 has been revised down by 34%. Nvidia is the most impacted, accounting for 66% of the global chip shipment reduction, with its 2030 shipment forecast—based on revenue from computing—also reduced by as much as 66%.

